[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 24 of about 24
1. Mendivil A, Schuler KM, Gehrig PA: Non-endometrioid adenocarcinoma of the uterine corpus: a review of selected histological subtypes. Cancer Control; 2009 Jan;16(1):46-52
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-endometrioid adenocarcinoma of the uterine corpus: a review of selected histological subtypes.
  • BACKGROUND: Understanding the etiology, presentation, evaluation, and management of selected non-endometrioid endometrial adenocarcinomas of the uterine corpus is needed to define optimal treatment regimens.
  • METHODS: The pathology and treatment of selected non-endometrioid endometrial adenocarcinomas of the uterus are reviewed and summarized.
  • RESULTS: The most common non-endometrioid histology is papillary serous (10%), followed by clear cell (2% to 4%), mucinous (0.6% to 5%), and squamous cell (0.1% to 0.5%).
  • Some non-endometrioid endometrial carcinomas behave more aggressively than the endometrioid cancers such that even women with clinical stage I disease often have extrauterine metastasis at the time of surgical evaluation.
  • Therefore, when technically and medically feasible, comprehensive surgical staging is helpful for women with non-endometrioid endometrial cancer histology.
  • While whole abdominal radiotherapy has a limited role in early-stage uterine papillary serous carcinoma (UPSC) and clear cell carcinoma (CC), there may be a role for postoperative chemotherapy and volume-directed radiotherapy in both early-stage UPSC and CC.
  • In the setting of optimally debulked advanced-stage disease, a combination of radiation and chemotherapy may be indicated.
  • CONCLUSIONS: UPSC and CC are managed similarly since sufficient data to separate treatment recommendations are lacking.
  • Because both histologies are associated with a high rate of recurrence, adjuvant therapy is recommended even in women with early-stage disease.
  • The remaining cell types should be treated similar to endometrioid or other low-grade histologies.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / therapy. Uterine Neoplasms / pathology. Uterine Neoplasms / therapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Clinical Trials as Topic. Female. Gynecologic Surgical Procedures. Humans. Prognosis. Radiotherapy

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19078929.001).
  • [ISSN] 1526-2359
  • [Journal-full-title] Cancer control : journal of the Moffitt Cancer Center
  • [ISO-abbreviation] Cancer Control
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 51
  •  go-up   go-down


2. Srikantia N, B R, A G R, Kalyan SN: Endometrioid endometrial adenocarcinoma in a premenopausal woman with multiple organ metastases. Indian J Med Paediatr Oncol; 2009 Apr;30(2):80-3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrioid endometrial adenocarcinoma in a premenopausal woman with multiple organ metastases.
  • Endometrial adenocarcinoma is the third common malignancy of the female genital tract occurring most often in the postmenopausal age group.
  • We present an unusual case of endometrial adenocarcinoma in a premenopausal woman with simultaneous metastases in brain, liver, skin and skeletal system, within one month of completion of treatment.
  • The role of adjuvant/concurrent chemotherapy in addition to radiotherapy in high risk cases is discussed along with the review of literature.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 1997 Jun;65(3):530-3 [9190989.001]
  • [Cites] Int J Gynecol Pathol. 2002 Jul;21(3):281-4 [12068176.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 May 1;59(1):168-73 [15093913.001]
  • [Cites] Gynecol Oncol. 2004 May;93(2):524-8 [15099973.001]
  • [Cites] Expert Rev Anticancer Ther. 2004 Aug;4(4):679-89 [15270671.001]
  • [Cites] Gynecol Oncol. 2004 Aug;94(2):333-9 [15297170.001]
  • [Cites] Gan To Kagaku Ryoho. 2008 Sep;35(9):1488-94 [18799902.001]
  • [Cites] Anticancer Res. 2009 May;29(5):1715-20 [19443392.001]
  • (PMID = 20596308.001).
  • [ISSN] 0975-2129
  • [Journal-full-title] Indian journal of medical and paediatric oncology : official journal of Indian Society of Medical & Paediatric Oncology
  • [ISO-abbreviation] Indian J Med Paediatr Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2885881
  • [Keywords] NOTNLM ; Adjuvant chemotherapy / endometrial carcinoma / multiple organ metastases
  •  go-up   go-down


3. Wethington SL, Barrena Medel NI, Wright JD, Herzog TJ: Prognostic significance and treatment implications of positive peritoneal cytology in endometrial adenocarcinoma: Unraveling a mystery. Gynecol Oncol; 2009 Oct;115(1):18-25
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance and treatment implications of positive peritoneal cytology in endometrial adenocarcinoma: Unraveling a mystery.
  • OBJECTIVE: Review the literature on positive peritoneal cytology in endometrioid endometrial adenocarcinoma, its prognostic value, proposed treatment strategies, and future avenues of investigation.
  • METHODS: PubMed search of articles pertaining to stage IIIA endometrioid endometrial adenocarcinoma identified over 50 articles that were reviewed.
  • In low-risk stage IIIA1 endometrial carcinoma patients, the rate of recurrence is 4.1%.
  • In contrast, in high-risk stage IIIA1 endometrial carcinoma patients the rate of recurrence is 32%, a statistically significant difference (p<0.001).
  • CONCLUSIONS: To date there is no definitive consensus on the prognostic significance of positive peritoneal cytology alone.
  • Adjuvant therapy for low-risk stage IIIA diseased may or may not be of benefit.
  • High-risk disease should be treated with chemotherapy, radiation or a combination thereof.
  • A prospective, multicenter trial of comprehensively surgically staged patients with stage IIIA endometrial cancer is indicated in order to clearly define prognosis and treatment for these patients.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Carcinoma, Endometrioid / therapy. Endometrial Neoplasms / pathology. Endometrial Neoplasms / therapy. Peritoneal Cavity / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19632708.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


Advertisement
4. Fujimura H, Kikkawa F, Oguchi H, Nakashima N, Mizutani S: Adjuvant chemotherapy including cisplatin in endometrial carcinoma. Gynecol Obstet Invest; 2000;50(2):127-32
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant chemotherapy including cisplatin in endometrial carcinoma.
  • To determine the outcome of patients with endometrial endometrioid adenocarcinoma following adjuvant chemotherapy, CAP (cyclophosphamide, pirarubicin and cisplatin) and EP (etoposide and cisplatin) were assigned at random to patients with Ic or more advanced stage carcinoma, and their efficacy was compared.
  • These patients were treated by the Tokai Endometrial Cancer Study Group (Nagoya University and related institutions) between January 1992 and June 1996.
  • In conclusion, the EP chemotherapy had no significant advantage in terms of survival and disease-free survival compared to CAP, although these rates were superior in the EP group compared to the CAP group.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Endometrial Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. CA-125 Antigen / analysis. Chemotherapy, Adjuvant. Cyclophosphamide / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Doxorubicin / analogs & derivatives. Etoposide / administration & dosage. Female. Humans. Lymphatic Metastasis. Middle Aged. Multivariate Analysis. Survival Rate. Treatment Outcome

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 S. Karger AG, Basel.
  • (PMID = 10965198.001).
  • [ISSN] 0378-7346
  • [Journal-full-title] Gynecologic and obstetric investigation
  • [ISO-abbreviation] Gynecol. Obstet. Invest.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / CA-125 Antigen; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin; CAP-1 protocol; VP-P protocol
  •  go-up   go-down


5. Tao X, Kavanagh JJ: Chemotherapy for gynecological malignancies in organ transplantation patients: report of two cases. Int J Gynecol Cancer; 2008 Nov-Dec;18(6):1376-80
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy for gynecological malignancies in organ transplantation patients: report of two cases.
  • Treatment, especially chemotherapy, in these patients should take into consideration their renal function and the effects of immunosuppressive agents.
  • We here present two case reports of patients with chemotherapy-treated gynecological malignancies who had previously received organ transplantation.
  • The first case, a rare occurrence of simultaneous carcinomas of the uterine corpus and ovary, is the first such report in the English literature describing chemotherapy for concurrent serous papillary ovarian carcinoma and endometrioid endometrial carcinoma in a renal transplant patient.
  • The second case report, describing chemotherapy for cervical cancer following two organ transplantation, also rare, is the first such report in the English literature and the first report of cervical cancer after heart-kidney transplantation.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Adenosquamous / drug therapy. Heart Transplantation. Kidney Transplantation. Ovarian Neoplasms / drug therapy. Uterine Neoplasms / drug therapy
  • [MeSH-minor] Disease Progression. Female. Graft Survival / drug effects. Humans. Immunosuppressive Agents / pharmacology. Middle Aged


6. Tanase Y, Kawaguchi R, Haruta S, Kanayama S, Yamada Y, Kobayashi H: [Adjuvant chemotherapy of paclitaxel plus carboplatin in uterine corpus cancer--comparison with cisplatin, adriamycin plus cyclophosphamide]. Gan To Kagaku Ryoho; 2006 Jul;33(7):945-50
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adjuvant chemotherapy of paclitaxel plus carboplatin in uterine corpus cancer--comparison with cisplatin, adriamycin plus cyclophosphamide].
  • The therapeutic efficacy and adverse reactions were compared between 14 patients who received TJ therapy using paclitaxel (PTX) and carboplatin (CBDCA) and 39 who received CAP therapy using cyclophosphamide (CPA), doxorubicin (DXR) and cisplatin (CDDP) as postoperative chemotherapy for cancer of the uterine body.
  • In TJ therapy, PTX (175 mg/m(2)) and CBDCA (AUC 5) were administered on Day 1 (every 3 weeks), while in CAP therapy, CPA (500 mg/m(2)), DXR (40 mg/m(2)) and CDDP (50 mg/m(2)) were administered on Day 1 (every 4 weeks).
  • Grade 3 or severe non-hematologic toxicities included nausea (0%, 15.4%) and vomiting (0%, 12.8%) with significantly higher incidence in the CAP therapy group (p=0.0000736, p=0.000736), peripheral sensory disturbance (7.1%, 0%) and arthralgia (7.1%, 0%) with significantly higher incidence in the TJ therapy group (p=0.00129, p=0.00000538).
  • TJ therapy is thought to be as effective as CAP therapy, and can be safely conducted, although precautions are required regarding arthralgia and neuropathy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Endometrioid / drug therapy. Uterine Neoplasms / drug therapy
  • [MeSH-minor] Aged. Carboplatin / administration & dosage. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Drug Administration Schedule. Female. Humans. Hysterectomy. Middle Aged. Neutropenia / chemically induced. Paclitaxel / administration & dosage. Survival Rate. Thrombocytopenia / chemically induced

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16835485.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


7. Rice LW, Stone RL, Xu M, Galgano M, Stoler MH, Everett EN, Jazaeri AA: Biologic targets for therapeutic intervention in endometrioid endometrial adenocarcinoma and malignant mixed müllerian tumors. Am J Obstet Gynecol; 2006 Apr;194(4):1119-26; discussion 1126-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biologic targets for therapeutic intervention in endometrioid endometrial adenocarcinoma and malignant mixed müllerian tumors.
  • OBJECTIVE: The purpose of this study was to investigate the AKT signaling cascade in endometrial cancers and to assess its therapeutic potential.
  • STUDY DESIGN: Western blotting and immunohistochemistry were used to investigate the expression of estrogen receptor, progesterone receptor, HER2, AKT, and 4EBP1 proteins in 27 atrophic endometria, 31 grade 1 and 24 grade 3 endometrioid endometrial cancers, and 19 malignant mixed müllerian tumors.
  • RESULTS: Malignant mixed müllerian tumors and grade 3 endometrioid endometrial cancers demonstrated higher levels of AKT and 4EBP1 activation and hormone receptor loss compared with grade 1 endometrioid endometrial cancers and atrophic samples.
  • In endometrial cancer cell-lines, AKT cascade inhibitors decreased cell proliferation by apoptosis and cell cycle arrest.
  • CONCLUSION: AKT cascade activation in grade 3 endometrioid endometrial cancers and malignant mixed müllerian tumors is a novel finding.
  • Apoptosis and growth arrest that results from AKT inhibition expose opportunities for therapeutic intervention.
  • [MeSH-major] Carcinoma, Endometrioid / drug therapy. Endometrial Neoplasms / drug therapy. Mixed Tumor, Mullerian / drug therapy. Oncogene Protein v-akt / antagonists & inhibitors

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16580307.001).
  • [ISSN] 1097-6868
  • [Journal-full-title] American journal of obstetrics and gynecology
  • [ISO-abbreviation] Am. J. Obstet. Gynecol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA44579
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.11.1 / Oncogene Protein v-akt
  •  go-up   go-down


8. Mariani A, Webb MJ, Keeney GL, Haddock MG, Aletti G, Podratz KC: Stage IIIC endometrioid corpus cancer includes distinct subgroups. Gynecol Oncol; 2002 Oct;87(1):112-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stage IIIC endometrioid corpus cancer includes distinct subgroups.
  • OBJECTIVE: Because stage IIIC corpus cancer is a heterogeneous substage, the outcomes of patients with stage IIIC disease were assessed according to the extent of extrauterine disease.
  • METHODS: From 1984 through 1993, 51 patients with surgical stage IIIC corpus cancer were treated at our institution; 5 patients had tumors with nonendometrioid histologic features and were excluded from the analyses.
  • Of the 46 patients with endometrioid carcinoma, 22 had lymph nodes as the only site of extrauterine disease (stage IIIC(0)) and 24 also had peritoneal cytologic, uterine serosal, adnexal, or vaginal involvement or a combination of these (stage IIIC(ab)).
  • Of the 22 patients with stage IIIC(0) endometrioid cancer, 21 had adjuvant radiotherapy (1 also received chemotherapy) and 1 was not treated.
  • Of the 24 patients with stage IIIC(ab) cancer, 16 received adjuvant radiotherapy (1 had concomitant chemotherapy), 2 had chemotherapy, 4 had hormonal therapy, and 2 were not treated.
  • CONCLUSION: Assessment of CSS, RFS, and sites of relapse suggests that FIGO surgical stage IIIC endometrioid corpus cancer includes two distinct and readily separable subgroups:.
  • (1) stage IIIC(0), nodal involvement only, and (2) stage IIIC(ab), nodal plus cytologic, uterine serosal, adnexal, or vaginal involvement, or a combination of these.
  • Our results also suggest that different treatment strategies are needed for these subgroups.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Endometrial Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Middle Aged. Neoplasm Staging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12468351.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. Rubatt JM, Slomovitz BM, Burke TW, Broaddus RR: Development of metastatic endometrial endometrioid adenocarcinoma while on progestin therapy for endometrial hyperplasia. Gynecol Oncol; 2005 Nov;99(2):472-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Development of metastatic endometrial endometrioid adenocarcinoma while on progestin therapy for endometrial hyperplasia.
  • BACKGROUND: Conservative treatment with progestins is a reasonable treatment option for endometrial complex atypical hyperplasia and, in the experimental setting, for some women with grade 1 endometrial endometrioid adenocarcinoma.
  • The risk of progression to a high-stage endometrial cancer is quite low, with only two previously reported cases in the English literature.
  • CASE: A 40-year-old woman with endometrial complex atypical hyperplasia diagnosed by dilatation and curettage was managed conservatively with progestin therapy (initially, megesterol acetate; then, a combination oral contraceptive).
  • More than 2 years after her original diagnosis, she developed endometrial endometrioid adenocarcinoma, FIGO grade 2, with lymph node metastasis.
  • CONCLUSION: Currently, there are no good criteria for predicting which patients with complex atypical hyperplasia/grade 1 endometrioid adenocarcinoma will optimally respond to progestin therapy.
  • There is some evidence that endometrial complex hyperplasia demonstrating loss of MLH1 protein by immunohistochemistry is strongly related to subsequent or concurrent endometrial cancer, especially tumors of higher grade and stage.
  • In a woman with a biopsy diagnosis of endometrial hyperplasia, evaluation of MLH1 protein status by immunohistochemistry may provide useful information when medical management is being considered.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Endometrial Hyperplasia / drug therapy. Endometrial Hyperplasia / pathology. Endometrial Neoplasms / pathology. Progestins / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16099019.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 1P50CA098258-01; United States / NCI NIH HHS / CN / N01-CN-05127
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Progestins
  •  go-up   go-down


10. Dahmoun M, Boman K, Cajander S, Bäckström T: Intratumoral effects of medroxy-progesterone on proliferation, apoptosis, and sex steroid receptors in endometrioid endometrial adenocarcinoma. Gynecol Oncol; 2004 Jan;92(1):116-26
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intratumoral effects of medroxy-progesterone on proliferation, apoptosis, and sex steroid receptors in endometrioid endometrial adenocarcinoma.
  • OBJECTIVE: The effects of progesterone on proliferation and apoptosis are studied in a scrutinized evaluation of endometrial carcinoma before, during, and after progesterone therapy.
  • METHODS: A total of 29 endometrial carcinomas were studied with in situ evaluation of Ki-67 proliferation marker, estrogen and progesterone receptors (ER and PR), and bcl-2 and p53 immunohistochemistry in the epithelial part of the tumor.
  • In biopsy 1, before the therapy, Ki-67 ER, and PR were studied also in stroma.
  • RESULTS: Proliferation (Ki-67) was decreased in grade 1 (G1) and grade 2 (G2) tumors during progesterone therapy both in overall evaluation (Ki) and particularly in the areas of maximal proliferation (Ki-max).
  • Apoptosis as well as bcl-2 and ER expression were unchanged during therapy and withdrawal.
  • [MeSH-major] Adenocarcinoma / drug therapy. Apoptosis / drug effects. Endometrial Neoplasms / drug therapy. Medroxyprogesterone / pharmacology. Receptors, Estrogen / metabolism. Receptors, Progesterone / metabolism
  • [MeSH-minor] Aged. Aged, 80 and over. Cell Division / drug effects. Female. Humans. Immunohistochemistry. Ki-67 Antigen / metabolism. Middle Aged. Proto-Oncogene Proteins c-bcl-2 / metabolism. Tumor Suppressor Protein p53 / metabolism

  • Hazardous Substances Data Bank. MEDROXYPROGESTERONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14751147.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; 0 / Tumor Suppressor Protein p53; HSU1C9YRES / Medroxyprogesterone
  •  go-up   go-down


11. Myriokefalitaki E, Iavazzo C, Vorgias G, Akrivos T: A two eterochronous primary gynaecological malignancies of different origin. Bratisl Lek Listy; 2009;110(11):726-8
MedlinePlus Health Information. consumer health - Vaginal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Curettage revealed an endometrial cancer.
  • Histology showed an endometrioid adenocarcinoma of endometrium stage Ib, moderately differentiated.
  • No additional therapy was given.
  • Although, recurrence on vaginal cuff was possible, the biopsies of anterior vaginal wall showed a poorly differentiated squamous cell carcinoma of the vagina.
  • The patient was classified as stage II vaginal carcinoma and underwent complete radiotherapy and chemotherapy.
  • CONCLUSION: This case indicates that female genital carcinomas of different histological origins may occur with minimal time-interval, even in the absence of known predisposing factors like previous chemo-radiotherapy, HPV infection or diethylstilbestrol exposure.
  • [MeSH-major] Carcinoma, Endometrioid / diagnosis. Carcinoma, Squamous Cell / diagnosis. Endometrial Neoplasms / diagnosis. Neoplasms, Second Primary / diagnosis. Vaginal Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20120445.001).
  • [ISSN] 0006-9248
  • [Journal-full-title] Bratislavské lekárske listy
  • [ISO-abbreviation] Bratisl Lek Listy
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Slovakia
  •  go-up   go-down


12. Bermudez Wagner KM, Thomas MB, Miyamoto C, Micaily B, Hernandez E: Tailored surgical staging and radiation therapy in clinical stage I endometrioid endometrial adenocarcinoma (EEA). J Clin Oncol; 2009 May 20;27(15_suppl):e16511

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tailored surgical staging and radiation therapy in clinical stage I endometrioid endometrial adenocarcinoma (EEA).
  • : e16511 Background: Pelvic lymph node dissection (LND) requirement to adequately stage endometrial cancer has been subject of debate.
  • We conducted an outcome analysis of clinical stage I endometrioid endometrial adenocarcinoma (EEA) patients who underwent surgery with tailored LND and adjuvant therapy (radiation (RT) or chemotherapy) between 1997 and 2008.
  • CONCLUSIONS: In patients with EEA, a tailored approach to LND and adjuvant therapy results in good outcome, but many still have therapy-associated adverse events.
  • Although no difference was found in OS between patients who underwent LND and those who did not, similar survival for patients with stages I and IIIC suggests that therapy directed by the knowledge of nodal status may have an impact on survival.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960757.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Toyoda H, Hirai T, Ishii E: Alpha-fetoprotein producing uterine corpus carcinoma: A hepatoid adenocarcinoma of the endometrium. Pathol Int; 2000 Oct;50(10):847-52

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alpha-fetoprotein producing uterine corpus carcinoma: A hepatoid adenocarcinoma of the endometrium.
  • A case of alpha-fetoprotein (AFP) producing endometrial carcinoma in a 60-year-old Japanese woman is presented.
  • On admission a uterine corpus mass and high serum AFP concentration (31950 ng/mL) was noted.
  • Histologically, the biopsy specimen taken from the uterine mass showed a poorly differentiated endometrial carcinoma and a radical hysterectomy was subsequently performed.
  • The postoperative serum AFP value transiently decreased with chemotherapy, however, lung metastases were found and the patient died 12 months following surgery.
  • The resected uterus had a necrotic tumor, 6 x 5 x 4 cm in size, filling the endometrial cavity, characterized by exophytic growth with infiltration in the myometrium.
  • Histologically, the tumor was composed of the main medullary carcinoma area with microcysts and admixed small areas of well-differentiated endometrioid adenocarcinoma, accompanied by a smooth transition with one another.
  • Based on these findings, this uterine corpus tumor was regarded as hepatoid variant of endometrial carcinoma.
  • Although the histogenesis remains controversial, we assume the hypothesis that the tumor may arise in the endometrium per se in association with abnormal differentiation of muellerian duct elements.
  • [MeSH-major] Adenocarcinoma / pathology. Endometrial Neoplasms / pathology. alpha-Fetoproteins / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11107058.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] AUSTRALIA
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / alpha-Fetoproteins
  •  go-up   go-down


14. Takano M, Shibasaki T, Sato K, Aida S, Kikuchi Y: Malignant mixed Mullerian tumor of the uterine corpus with alpha-fetoprotein-producing hepatoid adenocarcinoma component. Gynecol Oncol; 2003 Nov;91(2):444-8
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant mixed Mullerian tumor of the uterine corpus with alpha-fetoprotein-producing hepatoid adenocarcinoma component.
  • OBJECTIVES: Hepatoid adenocarcinoma is a rare tumor and has the histological coexistence of well-differentiated adenocarcinoma and nests of hepatoid cells with immunoreactivity for alpha-fetoprotein (AFP).
  • A case of hepatoid adenocarcinoma in malignant mixed Mullerian tumor of the uterus is presented with a review of the literature.
  • Histologically, the tumor was composed of endometrioid adenocarcinoma, neoplastic hepatoid cells, and sarcoma component including leiomyosarcoma and rhabdomyosarcoma.
  • After operation followed by six courses of platinum-based chemotherapy, serum levels of AFP dropped into normal range.
  • CONCLUSIONS: This is, to our knowledge, the first report of malignant mixed Mullerian tumor of the uterus with an AFP-producing hepatoid adenocarcinoma component.
  • [MeSH-major] Carcinoma, Hepatocellular / metabolism. Carcinoma, Hepatocellular / pathology. Mixed Tumor, Mullerian / metabolism. Mixed Tumor, Mullerian / pathology. Uterine Neoplasms / metabolism. Uterine Neoplasms / pathology. alpha-Fetoproteins / biosynthesis

  • Genetic Alliance. consumer health - Malignant mixed Mullerian tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14599882.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / alpha-Fetoproteins
  • [Number-of-references] 17
  •  go-up   go-down


15. Taşkin EA, Taşkin S, Berker B, Erol E, Dünder I, Söylemez F: Aggressive mixed type endometrial carcinoma in a young woman with rapid progression and fatal outcome. Arch Gynecol Obstet; 2008 Jan;277(1):71-3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aggressive mixed type endometrial carcinoma in a young woman with rapid progression and fatal outcome.
  • INTRODUCTION: Endometrial carcinoma in young ages is uncommon and tends to be a well differentiated endometrioid type and has an excellent prognosis.
  • Nevertheless, in this report mixed type endometrial cancer including serous, clear cell and endometrioid components in a young patient with rapid progression and fatal outcome is presented.
  • Transabdominal ultrasonography demonstrated 30 x 27 mm intramural mass consistent with leiomyoma in uterine corpus posterior.
  • The patient did not permit any vaginal intervention including endometrial sampling, therefore laparotomy was decided.
  • Mixed type endometrial carcinoma was diagnosed and she was treated with comprehensive surgery plus adjuvant chemotherapy.
  • CONCLUSION: We suggest that persistent uterine bleeding associated with severe anemia should be evaluated for malignancy even in young women to avoid delay in diagnosis.
  • Imaging studies especially magnetic resonance imaging may be helpful when endometrial sampling cannot be done.
  • [MeSH-major] Endometrial Neoplasms / pathology. Mixed Tumor, Malignant / pathology
  • [MeSH-minor] Adult. Anemia / etiology. Chemotherapy, Adjuvant. Fatal Outcome. Female. Humans. Menorrhagia / etiology. Neoplasm Invasiveness. Neoplasm Metastasis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17639438.001).
  • [ISSN] 0932-0067
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


16. Zepiridis L, Zafrakas M, Theodoridis TD, Kaplanis K, Dinas KK, Bontis JN: A unique case of palatinate tonsil metastasis from endometrial cancer. Eur J Gynaecol Oncol; 2009;30(2):229-30
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A unique case of palatinate tonsil metastasis from endometrial cancer.
  • A case of a 55-year-old woman presenting with a palatinate tonsil tumour two and half years after primary diagnosis of endometrioid endometrial adenocarcinoma (FIGO Stage IB, G2) and six months after local disease recurrence is presented.
  • The tonsillar malignancy was poorly differentiated and tumour cells were immunohistochemically positive to LMW keratin and EMA, and negative to HMW keratin and LCA, strongly suggesting a possible endometrial origin of the tumour.
  • Metastatic disease was treated with systemic chemotherapy, but the patient soon succumbed due to rapid disease progression.
  • In conclusion, a unique case of a palatinate tonsil tumour as the first metastatic site in an endometrial cancer patient is reported.
  • [MeSH-major] Adenocarcinoma / secondary. Endometrial Neoplasms / pathology. Tonsillar Neoplasms / secondary

  • Genetic Alliance. consumer health - Endometrial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19480265.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


17. McCluggage WG, Bryson C, Lamki H, Boyle DD: Benign, borderline, and malignant endometrioid neoplasia arising in endometriosis in association with tamoxifen therapy. Int J Gynecol Pathol; 2000 Jul;19(3):276-9
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign, borderline, and malignant endometrioid neoplasia arising in endometriosis in association with tamoxifen therapy.
  • Tamoxifen therapy may result in a variety of endometrial proliferative lesions, including adenocarcinoma, and as recently suggested, proliferative changes within endometriosis.
  • This report describes an endometrioid adenocarcinoma arising in ovarian endometriosis in a patient taking tamoxifen.
  • There were also foci of benign and borderline endometrioid adenofibroma in the same ovary and a synchronous endometrioid endometrial adenocarcinoma in the uterus.
  • The spectrum of benign, borderline, and malignant endometrioid neoplasia arising within endometriosis suggests that tamoxifen, as a result of its estrogenic effects, may cause proliferative and, in rare instances, malignant changes in endometriosis.
  • [MeSH-major] Adenocarcinoma / chemically induced. Carcinoma, Endometrioid / chemically induced. Endometrial Neoplasms / chemically induced. Endometriosis / pathology. Ovarian Neoplasms / chemically induced. Tamoxifen / adverse effects
  • [MeSH-minor] Breast Neoplasms / drug therapy. Estrogen Antagonists / adverse effects. Fallopian Tubes / surgery. Female. Humans. Hysterectomy. Middle Aged. Ovariectomy

  • Genetic Alliance. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10907178.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Estrogen Antagonists; 094ZI81Y45 / Tamoxifen
  •  go-up   go-down


18. Ferrandina G, Zannoni GF, Martinelli E, Vellone V, Prisco MG, Scambia G: Endometrial carcinoma recurring as carcinosarcoma: report of two cases. Pathol Res Pract; 2007;203(9):677-81

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrial carcinoma recurring as carcinosarcoma: report of two cases.
  • Endometrial carcinosarcoma is a rare, aggressive disease, accounting for approximately 3% of all uterine neoplasms.
  • The emergence of sarcomatous elements is considered the evolution of subclones arising from high grade endometrial carcinomas.
  • Here, we report two cases of primary endometrial carcinomas recurring as carcinosarcoma.
  • Case 1. a 58-year-old postmenopausal woman diagnosed to have a poorly differentiated endometrial endometrioid adenocarcinoma (FIGO stage IB) developed an intra-abdominal recurrence of disease after 17 months from diagnosis.
  • Histopathological analysis documented a biphasic neoplasia consisting of an epithelial (grade 3 endometrial endometrioid adenocarcinoma) and a sarcomatous component.
  • Salvage chemotherapy with cisplatin, ifosfamide, epirubicin, and then with taxotere was attempted.
  • A 56-year-old woman with a diagnosis of grade 3 endometrial adenosquamous carcinoma of the endometrium (FIGO stage IIIA) experienced pelvic recurrence after five months from completion of chemotherapy.
  • Definitive histology was malignant mixed mesodermal tumor with focal areas of chondrosarcomatous elements.
  • The patient was triaged to exclusive concomitant chemoradiotherapy and salvage chemotherapy.
  • We describe two cases of high grade endometrial carcinomas recurring as carcinosarcoma, thus providing evidence that the metaplastic sarcomatous evolution is a very rare event which can occur in patients with anaplastic endometrial cancer.
  • [MeSH-major] Carcinoma, Adenosquamous / pathology. Carcinoma, Endometrioid / secondary. Carcinosarcoma / secondary. Chondrosarcoma / secondary. Endometrial Neoplasms / pathology. Neoplasm Recurrence, Local / therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cell Differentiation. Combined Modality Therapy. Fatal Outcome. Female. Humans. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Salvage Therapy / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17646054.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


19. Camatte S, Morice P, Atallah D, Pautier P, Lhommé C, Haie-Meder C, Duvillard P, Castaigne D: Lymph node disorders and prognostic value of nodal involvement in patients treated for a borderline ovarian tumor: an analysis of a series of 42 lymphadenectomies. J Am Coll Surg; 2002 Sep;195(3):332-8
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • STUDY DESIGN: Forty-two patients were treated for BOT with a procedure that included lymphadenectomy.
  • Thirty-two patients underwent systematic lymphadenectomy, five because of associated cancer (uterine cervix or corpus) and five because of bulky nodes discovered during the surgical procedure.
  • One patient died of a complication of adjuvant therapy (leukemia after chemotherapy).
  • This procedure should be carried out in patients with serous tumor and enlarged lymph nodes.
  • [MeSH-minor] Adolescent. Adult. Aged. Carcinoma, Endometrioid / pathology. Carcinoma, Endometrioid / therapy. Combined Modality Therapy. Cystadenoma, Mucinous / pathology. Cystadenoma, Mucinous / therapy. Cystadenoma, Serous / pathology. Cystadenoma, Serous / therapy. Female. Humans. Lymph Node Excision. Middle Aged. Neoplasm Staging. Neoplasms, Complex and Mixed / pathology. Neoplasms, Complex and Mixed / therapy. Prognosis. Retrospective Studies. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12229940.001).
  • [ISSN] 1072-7515
  • [Journal-full-title] Journal of the American College of Surgeons
  • [ISO-abbreviation] J. Am. Coll. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Watanabe J, Watanabe K, Jobo T, Kamata Y, Kawaguchi M, Imai M, Okayasu I, Kuramoto H: Significance of p27 as a predicting marker for medroxyprogesterone acetate therapy against endometrial endometrioid adenocarcinoma. Int J Gynecol Cancer; 2006 Jan-Feb;16 Suppl 1:452-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Significance of p27 as a predicting marker for medroxyprogesterone acetate therapy against endometrial endometrioid adenocarcinoma.
  • We reported that p27 induced by medroxyprogesterone acetate (MPA) may be involved in the progestin-induced growth suppression of human endometrial adenocarcinoma cells.
  • This study aimed at investigating whether p27 expression could be a predicting marker to evaluate the effectiveness of MPA therapy.
  • The clinical responses of 15 patients with endometrial carcinoma treated with MPA were examined. p27 expression was evaluated by immunohistochemical staining.
  • Before MPA treatment, SP LIs in the effective and noneffective groups were 22.6 +/- 14.3% and 9.1 +/- 9.2%.
  • At 1-6 weeks in the MPA treatment, SP LIs increased in both groups and were significantly higher than those before the therapy.
  • The former was significantly higher than the latter. p27 expression could predict the effectiveness of MPA treatment for endometrial carcinoma at an early stage of the 4-month period in MPA therapy and could be a useful predicting marker for MPA.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Endometrioid / drug therapy. Endometrial Neoplasms / drug therapy. Proliferating Cell Nuclear Antigen / analysis
  • [MeSH-minor] Adult. Antineoplastic Agents, Hormonal / therapeutic use. Female. Humans. Immunohistochemistry. Medroxyprogesterone Acetate / therapeutic use. Predictive Value of Tests. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16515645.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Biomarkers, Tumor; 0 / Proliferating Cell Nuclear Antigen; 0 / p27 antigen; C2QI4IOI2G / Medroxyprogesterone Acetate
  •  go-up   go-down


21. Gadducci A, Cosio S, Spirito N, Cionini L: Clear cell carcinoma of the endometrium: a biological and clinical enigma. Anticancer Res; 2010 Apr;30(4):1327-34
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clear cell carcinoma of the endometrium: a biological and clinical enigma.
  • Clear cell carcinoma accounts for only 1 to 5.5% of all endometrial carcinomas, and it is often associated with an aggressive clinical behavior and a poor outcome.
  • According to the FIGO Annual Report 2006, 5-year overall survival was 62.5% for patients with this histological type compared with 83.2% for those with endometrioid carcinoma of the endometrium.
  • In contrast to endometrioid carcinoma and uterine papillary serous carcinoma (UPSC), the molecular pathways involved in the development of clear cell carcinoma are still unclear.
  • Literature data on the pattern of failures and the optimal treatment modalities of the clear cell carcinoma are not well defined, largely because most papers have assessed clear cell carcinoma and UPSC together because of their rarity.
  • Patients with clear cell carcinoma often experience relapse in the pelvis, in para-aortic nodes and at distant sites, whereas they do not seem to have a high propensity to fail in the abdomen.
  • Total abdominal hysterectomy and bilateral salpingo-oophorectomy with comprehensive surgical staging is the standard surgical treatment of patients with clear cell carcinoma of the endometrium, whereas pelvic irradiation, with or without brachytherapy and/or para-aortic irradiation, whole-abdomen irradiation, and chemotherapy have been widely employed as postoperative therapy.
  • An adequate molecular characterization of clear cell carcinoma of the endometrium is strongly warranted in order to identify new biological prognostic variables of the disease and to develop novel molecular targeted therapies.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Clear Cell / therapy. Endometrial Neoplasms / pathology. Endometrial Neoplasms / therapy

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20530448.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Greece
  • [Number-of-references] 73
  •  go-up   go-down


22. Oaknin A, Barretina MP, Morilla I: Muscle metastasis of low-grade endometrial carcinoma seven years after diagnosis: a case report. Eur J Gynaecol Oncol; 2010;31(1):114-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Muscle metastasis of low-grade endometrial carcinoma seven years after diagnosis: a case report.
  • BACKGROUND: Early-stage low-grade endometrial carcinoma has an excellent prognosis.
  • CASE: A 69-year-old woman underwent surgery for FIGO Stage IA, grade 1 endometrioid adenocarcinoma of the endometrium.
  • After failing hormone therapy, chemotherapy was administered.
  • CONCLUSION: Low-risk endometrial carcinoma can behave like a high-risk group.
  • Furthermore, this report describes, to our knowledge, the first case of endometrial carcinoma muscle metastasis.
  • [MeSH-major] Carcinoma, Endometrioid / secondary. Endometrial Neoplasms / pathology. Muscle Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20349796.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


23. Hahn HS, Yoon SG, Hong JS, Hong SR, Park SJ, Lim JY, Kwon YS, Lee IH, Lim KT, Lee KH, Shim JU, Mok JE, Kim TJ: Conservative treatment with progestin and pregnancy outcomes in endometrial cancer. Int J Gynecol Cancer; 2009 Aug;19(6):1068-73
Genetic Alliance. consumer health - Endometrial cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Conservative treatment with progestin and pregnancy outcomes in endometrial cancer.
  • INTRODUCTION: The purpose of this study was to evaluate the efficacy of conservative treatment with progestin and pregnancy outcomes in women with early-stage endometrial cancer.
  • METHODS: We retrospectively analyzed the medical records of 35 patients with endometrial adenocarcinoma, who were treated with progestin from January 1996 to December 2006.
  • Women with early-stage grade 1 endometrioid endometrial adenocarcinoma, who wanted to receive conservative treatment or preserve fertility, were included.
  • Complete remission (CR) was defined as no evidence of endometrial adenocarcinoma or hyperplasia.
  • Partial remission was diagnosed when the patient developed endometrial hyperplasia, and persistent disease was defined as residual endometrial adenocarcinoma by pathologic confirmation.
  • The median time to CR was 9 months (range, 2-12 months).
  • Of the 22 patients with CR, 9 (40.9%) had recurrent disease, and the median time to recurrence was 12 months (range, 8-48 months).
  • There were no congenital anomalies in babies associated with progestin treatment.
  • CONCLUSIONS: Conservative treatment with progestin can be considered a good therapeutic option in patients with well-differentiated early-stage endometrioid endometrial adenocarcinoma who wish to preserve their uteri or become pregnant.
  • [MeSH-major] Carcinoma, Endometrioid / drug therapy. Carcinoma, Endometrioid / rehabilitation. Endometrial Neoplasms / drug therapy. Endometrial Neoplasms / rehabilitation. Pregnancy Outcome. Progestins / therapeutic use
  • [MeSH-minor] Adult. Algorithms. Antineoplastic Agents, Hormonal / adverse effects. Antineoplastic Agents, Hormonal / therapeutic use. Female. Fertility / drug effects. Follow-Up Studies. Gynecologic Surgical Procedures / adverse effects. Humans. Infertility, Female / prevention & control. Medroxyprogesterone Acetate / adverse effects. Medroxyprogesterone Acetate / therapeutic use. Megestrol Acetate / adverse effects. Megestrol Acetate / therapeutic use. Pregnancy. Remission Induction / methods. Retrospective Studies. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19820370.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Progestins; C2QI4IOI2G / Medroxyprogesterone Acetate; TJ2M0FR8ES / Megestrol Acetate
  •  go-up   go-down


24. Utsunomiya H, Suzuki T, Ito K, Moriya T, Konno R, Sato S, Yaegashi N, Okamura K, Sasano H: The correlation between the response to progestogen treatment and the expression of progesterone receptor B and 17beta-hydroxysteroid dehydrogenase type 2 in human endometrial carcinoma. Clin Endocrinol (Oxf); 2003 Jun;58(6):696-703
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The correlation between the response to progestogen treatment and the expression of progesterone receptor B and 17beta-hydroxysteroid dehydrogenase type 2 in human endometrial carcinoma.
  • OBJECTIVE: In situ metabolism and synthesis of oestrogens are considered to play important roles in the pathogenesis and development of human endometrial endometrioid adenocarcinoma.
  • Approximately 3-5% of patients with these neoplasms are under age 40, some of whom have been treated with progestogen alone as a primary therapy for both atypical endometrial hyperplasia and adenocarcinoma in order to preserve their fertility.
  • Medroxyprogesterone acetate (MPA) has been used extensively in the treatment of both breast and endometrial disorders as an endocrine therapy.
  • However, details of the alterations of in situ oestrogen metabolism following progestogen treatment have yet to be fully elucidated.
  • DESIGN, PATIENTS AND MEASUREMENTS: In this study we examined the immunolocalization of 17beta-hydroxysteroid dehydrogenase (17beta-HSD) types 1 and 2, oestrogen receptor (ER), progesterone receptor (PR)A + PRB, PRB, and Ki67 in progestogen-treated endometrial endometrioid adenocarcinoma (16 cases).
  • We compared our findings both prior to and following treatment.
  • These findings were then correlated with the treatment outcome of individual patients in order to elucidate factors associated with the response to treatment.
  • RESULTS: 17beta-HSD type 2 immunoreactivity was detected in 8/16 cases examined, whereas 17beta-HSD type 1 immunoreactivity was undetected in all cases examined.
  • 17beta-HSD type 2 positive immunostaining, PRA + PRB labelling index (LI), and PRB/PRA + PRB ratio were all significantly higher in cases responding to the treatment than in those not responding.
  • There were no significant correlations between responsive and nonresponsive cases for positive 17beta-HSD type 1 immunostaining, Ki67 LI, ER LI and age.
  • There were no significant differences in the positive immunostaining for 17beta-HSD types 1 and 2, Ki67 LI, ER LI, PRA + PRB LI, age and PRB/PRA + PRB ratio between specimens taken prior to and following progestogen treatment.
  • CONCLUSION: These results suggest that in situ abundance of 17beta-HSD type 2 and PR, especially PRB, can predict the possible response of patients with endometrial carcinoma to progestogen treatment.
  • [MeSH-major] 17-Hydroxysteroid Dehydrogenases / analysis. Adenocarcinoma / drug therapy. Endometrial Neoplasms / drug therapy. Medroxyprogesterone / therapeutic use. Progesterone Congeners / therapeutic use. Receptors, Progesterone / analysis
  • [MeSH-minor] Adult. Biomarkers / analysis. Estradiol Dehydrogenases. Female. Follow-Up Studies. Humans. Immunohistochemistry / methods. Ki-67 Antigen / analysis. Receptors, Estrogen / analysis. Treatment Outcome

  • Hazardous Substances Data Bank. MEDROXYPROGESTERONE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12780745.001).
  • [ISSN] 0300-0664
  • [Journal-full-title] Clinical endocrinology
  • [ISO-abbreviation] Clin. Endocrinol. (Oxf)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Ki-67 Antigen; 0 / Progesterone Congeners; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; 0 / progesterone receptor A; 0 / progesterone receptor B; EC 1.1.- / 17-Hydroxysteroid Dehydrogenases; EC 1.1.1.62 / Estradiol Dehydrogenases; EC 1.1.1.62 / HSD17B2 protein, human; HSU1C9YRES / Medroxyprogesterone
  •  go-up   go-down






Advertisement